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BRAF mutations may identify
a clinically distinct subset
of glioblastoma
Samantha N. McNulty1,9, Katherine E. Schwetye1,9, Cole Ferguson1, Chad E. Storer2,
George Ansstas3,4, Albert H. Kim4,5, David H. Gutmann6, Joshua B. Rubin4,7,8,
Richard D. Head2* & Sonika Dahiya1,4*
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Prior studies
examining the mutational landscape of GBM revealed recurrent alterations in genes that regulate the
same growth control pathways. To this regard, ~ 40% of GBM harbor EGFR alterations, whereas BRAF
variants are rare. Existing data suggests that gain-of-function mutations in these genes are mutually
exclusive. This study was designed to explore the clinical, pathological, and molecular differences
between EGFR- and BRAF-mutated GBM. We reviewed retrospective clinical data from 89 GBM
patients referred for molecular testing between November 2012 and December 2015. Differences in
tumor mutational profile, location, histology, and survival outcomes were compared in patients with
EGFR- versus BRAF-mutated tumors, and microarray data from The Cancer Genome Atlas was used
to assess differential gene expression between the groups. Individuals with BRAF-mutant tumors
were typically younger and survived longer relative to those with EGFR-mutant tumors, even in the
absence of targeted treatments. BRAF-mutant tumors lacked distinct histomorphology but exhibited
unique localization in the brain, typically arising adjacent to the lateral ventricles. Compared to EGFRand IDH1-mutant tumors, BRAF-mutant tumors showed increased expression of genes related to a
trophoblast-like phenotype, specifically HLA-G and pregnancy specific glycoproteins, that have been
implicated in invasion and immune evasion. Taken together, these observations suggest a distinct
clinical presentation, brain location, and gene expression profile for BRAF-mutant tumors. Pending
further study, this may prove useful in the stratification and management of GBM.
Glioblastoma (WHO grade IV glioma, GBM) is a common malignancy of the central nervous system (CNS), constituting approximately 15% of all primarily brain tumors in a dults1. The median survival rate of a GBM patient is
approximately 14 months following the standard treatment of resection, irradiation, and chemotherapy2, a figure
that has remained essentially unchanged despite significant advances in defining the molecular pathogenesis of
these cancers3. With the dawn of the genomic era and the widespread implementation of clinical next-generation
sequencing (NGS), there has been an intense search for sequence variants with diagnostic, prognostic, and/or
therapeutic significance to inform optimized treatment protocols improve outcomes for GBM patients.
GBM harbor a wide array of molecular alterations, including combinations of point mutations, insertions and
deletions (indels), copy number variants, and epigenetic m
 odifications4. Some of these alterations correlate with
differences in clinical outcome and are used to diagnose and classify tumors and/or inform treatment decisions.
For example, mutations in IDH1 and IDH2 are the major stratifying features of diffuse g liomas4, and MGMT
promoter methylation is associated with longer overall survival and response to temozolomide t reatment2. The
biological and clinical significance of other recurrent mutations has yet to be d
 etermined4; however, molecular
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data are being actively mined in search of features that could enhance the clinical stratification of GBM and
reveal targets for existing and/or novel chemotherapeutic agents.
GBM frequently harbor mutations that activate mitogenic signaling pathways. Receptor tyrosine kinases
(RTKs) regulate growth factor signaling to increase cell proliferation, metabolism, and survival in response
to environmental cues5,6. Increased activation of the epidermal growth factor receptor (EGFR), a membrane
bound RTK, is common in GBM. This may occur via increased protein expression or via mutations that lead
to constitutive activity7. In a 2013 survey of 585 GBM, 45% had putative activating mutations (either copy
number amplifications, exon or domain deletions, point mutations, or combinations thereof) in EGFR4. Some
evidence (albeit inconsistent) suggests that gain-of-function alterations in EGFR could serve as an indicator of
poor prognosis within the current treatment paradigm8–10. They are also being explored as a potential target for
FDA-approved RTK i nhibitors11.
The serine/threonine-protein kinase, B-Raf (encoded by the BRAF gene) is a member of the RAS/RAF/MEK/
MAPK that functions downstream of EGFR. B-Raf inhibitors are approved for use in melanoma and non-small
cell lung cancer12,13, and ongoing clinical trials are exploring their use in brain tumors (see ClinicalTrials.gov
study IDs NCT03224767, NCT03973918, NCT02684058, etc.). The canonical BRAF p.V600E mutation occurs
in roughly half of all epithelioid GBM14, but it is rare in classic GBM15. As such, the 585-patient cohort described
above contained only 13 GBM specimens with putative gain-of-function BRAF amplifications and/or mutations4.
Activating alterations in EGFR and BRAF were reported in multiple GBM datasets, always appearing in a
mutually exclusive p
 attern4,16. This observation led us to speculate that GBM with activating alterations in BRAF
may constitute a biologically distinct entity. In this study, we sought to determine the clinical, pathologic, and
molecular differences between GBM with each of these mutations to better characterize their impact on the
diagnosis and management of GBM.

Materials and methods

Institutional case selection. Ninety-one consecutive formalin-fixed, paraffin-embedded (FFPE) GBM
specimens from 89 unique patients were submitted to Genomics and Pathology Services at Washington University in St. Louis (http://gps.wustl.edu) for testing between November 2012 and December 2015 (Supplemental
Table 1). All cases were initially reviewed by board-certified neuropathologists according to the WHO 2007
guidelines for classification of tumors of the C
 NS17 and appropriate ancillary diagnostic work-up was done
wherever necessary. Cases were re-classified according to WHO 2016 classification guidelines for the purpose
of this s tudy18.
Panel‑based next‑generation sequencing assays. The cases described in this study were derived
from three separate versions of the same comprehensive cancer assay. The assay version is listed for each case
in Supplemental Table 1, and the reportable genes for each assay version are listed in Supplemental Table 2. Ten
genes were present on all three assay versions: BRAF, CTNNB1, EGFR, IDH1, IDH2, KRAS, PDGFRA, PTEN,
TP53, and WT1.
DNA preparation and next‑generation sequencing. Next-generation sequencing was performed as
previously described19,20. FFPE blocks were reviewed by board-certified neuropathologists to identify regions
with sufficient neoplastic cellularity and tissue viability. Cores were punched from marked areas, and DNA was
isolated using a Qiagen QIAamp DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). DNA was sonicated with a Covaris Ultrasonicator (Woburn, MA), and assessed by an Agilent Bioanalyzer 2100 (Agilent,
Santa Clara, CA). NGS libraries were prepared using commercially available kits (Supplemental Table 3). Whole
genome shotgun libraries were enriched by hybridization capture using custom-designed oligonucleotide baits
(Supplemental Table 3) corresponding to the genes included on each version of the assay. Enriched libraries
were multiplexed and sequenced on the Illumina HiSeq2500 platform (Illumina, San Diego, CA) to generate
2 × 100 bp reads.
Sample pre‑processing and read alignment. Raw base call files (BCL files) were converted to fastq

format using Cassava v1.8 (Illumina) and de-multiplexed using in-house scripts. Paired-end reads were aligned
to the human reference assembly (UCSC hg19) using Novoalign (Novocraft Technologies, Selangor, Malaysia).
Alignment files were converted to BAM format with s amtools21, and duplicate reads were marked using Picard
Tools MarkDuplicates (https://broadinstitute.github.io/picard/). Coverage metrics are provided in Supplemental
Table 4.

Variant prediction, annotation, and interpretation. Variant calling methods are outlined in Supple-

mental Table 3. Aligned read depth at each chromosomal position was determined using SAMtools mpileup21,22.
Insertion and deletion (indel) variants ≤ 21 bp were called using Genome Analysis Toolkit’s (GATK23) Unified
Genotyper with the following cutoffs: depth ≥ 50 reads, Fisher strand bias ≤ 75, and not adjacent to a homopolymer run > 7 bp. Single nucleotide variants (SNVs) were called using either Genome Analysis Toolkit’s (GATK)
Unified Genotyper or V
 arScan224 with the following cutoffs: depth ≥ 50 reads, base quality ≥ 20, mapping quality ≥ 30, Fisher strand bias ≤ 75, and variant allele fraction (VAF) > 3%. SNVs and indels present in reportable
gene sets were subjected to annotation and clinical interpretation and were included in the patient’s medical
record. Polymorphisms represented in public human genomic variation databases (gnomAD, ExAC, dbSNP,
dbNSFP, NHLBI ESP) were discarded from this analysis. Remaining non-synonymous variants are listed in
Supplemental Table 1. Variants were classified as pathogenic or likely pathogenic based on established c riteria25.
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Fluorescence in situ hybridization. Formalin fixed paraffin embedded blocks were sectioned at 5 µm

and routinely processed using the Vysis EGFR/CEP7 FISH probe kit (Abbott Molecular Inc., Glean Oaks, IL)
and counterstained with DAPI II. Stained slides were viewed using a BX61 fluorescent microscope (Olympus,
Melville, NY, USA) and photographed with a Jai Progressive Scan camera and CytoVision Imaging System (Leica
Biosystems, Wetzlar, Germany). Two-hundred interphase nuclei were examined in each specimen. Polysomies
and monosomies were determined based on centromere enumerating probes. Focal gains and losses were determined based on signal ratios from locus-specific versus centromere enumerating probes.

Microarray‑based gene expression studies. Primary, IDHwt, GBM specimens were selected from a
TCGA dataset (Firehose Legacy, https://www.cbioportal.org/study?id=gbm_tcga) based on the presence of activating point mutations in EGFR and IDH1, and BRAF p.V600E mutations (Supplemental Table 5). CEL files
from the selected cases were downloaded. Normalized signal values were generated using Expression Console
v4.1.1 (Affymetrix, ThermoFisher Scientific, Waltham, MA) using the robust multichip average algorithm, and
detection p-values were calculated using the MAS5 algorithm. Probe-sets were filtered based on the detection
p-value; only those corresponding to coding genes were maintained in this analysis. Differentially expressed
genes were determined using limma26 with fold change cutoff of ≥ 2 and a false-discovery rate (FDR) cutoff
of ≤ 0.05.
Biological theme enrichment analysis. CompBio software (https://www.percayai.com/) was used to

identify biological themes that were enriched among the differentially expressed genes. This is accomplished
with an automated Biological Knowledge Generation Engine (BKGE) that extracts abstracts from PubMed that
reference the genes contained in the input list (i.e., the differentially expressed genes identified in the microarray
analysis) and uses contextual language processing and a biological language dictionary to compute the statistical
enrichment of biological concepts that co-occur with the input genes more frequently than would be expected by
random chance. Related concepts derived from the list of differentially expressed genes are further clustered into
higher-level themes. Scoring of concept and theme enrichment is accomplished using a multi-component function referred to as the Normalized Enrichment Score (NES). The first component utilizes an empirical p-value
derived from several thousand random entity lists of a size that is comparable to the users input entity list to
define the rarity of a given entity-concept event. The second component, effectively representing the fold enrichment, is based on the ratio of the concept enrichment score to the mean of that concept’s enrichment score across
the set of randomized entity data. As such, the NES reflects both the rarity of the co-occurrence of the input
genes with the concept as well as the degree of overall enrichment. Based on these empirical criteria, observed
entity-concept scores above 10.0, 100.0, and 1,000.0 are labeled as moderate, marked, or high in level of enrichment above random. Themes scoring above 500.0, 1,000.0, and 5,000.0 are labeled similarly. In this study, the
top 25 most enriched themes with scores > 1000.0 for each condition were subjected to manual annotation and
further analysis (Supplemental Fig. 1).

Ethics approval. The institutional review board of Washington University School of Medicine determined

that this retrospective study of de-identified data did not fit the definition of human subjects research; thus, no
IRB protocol was required.

Consent to participate. Not applicable.
Consent for publication. All authors of this manuscript have directly participated in the planning, analysis, and/or editing of this study, and approved the publication of this work.

Results

Specimens and clinical data. Ninety-one GBM (WHO grade IV) specimens from 89 unique patients

were submitted for targeted NGS between November 2012 and December 2015 (Supplemental Table 1). These
specimens included 87 primary GBM (IDH1 and IDH2 wild type, IDHwt) and four secondary GBM with mutations in IDH1. The male:female ratio among these patients was approximately 2:1 (56 M:33F). Patients ranged
in age from 9 to 83 years at the age of biopsy (average 55.10 ± 14.97 years). Three pediatric/adolescent GBM
(patients ≤ 18 years) were included in this cohort. One patient presented at age 12 with a GBM centered in the
thalamic region and again at age 18 with a recurrence in the posterior fossa. The other two pediatric patients had
been diagnosed with other cancers (desmoplastic infantile ganglioglioma and acute lymphoblastic leukemia)
prior to the development of GBM.

EGFR mutations. Twenty-one of the specimens in our dataset (23.1%) harbored point mutations in EGFR
(Fig. 1, Supplemental Table 1). Two specimens had EGFR p.G589V mutations; seven others had mutations in the
extracellular domain (p.A289T, n = 1; p.A289D, n = 2; p.A289V, n = 4; Fig. 1, Supplemental Fig. 2). These mutations are common in GBM and are known to drive autophosphorylation and activation of EGFR in the absence
of ligand7,27. The remaining 12 EGFR mutations were classified as variants of uncertain clinical significance (see
methods for details); their impact on protein activity is unknown.
Seventy-seven specimens were sent for analysis by FISH in addition to NGS. Thirty-three of these tested
positive for EGFR gene amplification. Thirteen of the 33 had point mutations within the amplified gene (Fig. 1,
Supplemental Table 1).
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Comparison

Up

BRAF mutation versus EGFR mutation

305

Down
156

BRAF mutation versus IDH1 mutation

965

1078

EGFR mutation versus IDH1 mutation

370

345

Table 1.  Differentially expressed gene count in comparisons of three molecularly distinct sub-types of
glioblastoma.

Figure 1.  Mutations found in ninety-one specimens of glioblastoma. Ninety-one glioblastoma specimens from
89 unique patients were subjected to next-generation sequencing on a small gene panel used for routine clinical,
diagnostic testing. Non-synonymous mutations are shown in nine genes that were included in all assay versions;
common population polymorphism were excluded. Ancillary testing for EGFR amplification was performed via
fluorescence in situ hybridization for 77 specimens as part of the diagnostic workup.

BRAF mutations. Five specimens from our cohort had point mutations in BRAF (Fig. 1, Supplemental
Table 1). One of these was the canonical p.V600E mutation (VAF 50.2%), which is known to increase kinase
activity and drive oncogenesis28. While the other four mutations classified as variants of uncertain functional/
clinical significance according to standard criteria (see methods for details), they were all located within the
tyrosine kinase domain (Supplemental Fig. 2). In absence of a germline control (typically unavailable in the
clinical setting), we take the VAF of the mutations (ranging from 10.0–26.0%) and their absence or rarity in databases of human genomic variation (e.g., gnomAD, see methods) as soft indications that they are somatic rather
than germline polymorphisms. A search of the COSMIC d
 atabase29 showed that the p.K483E and p.H574Q
mutations found in tumors GBM_01 and GBM_08, respectively, have both been reported in the context of other
cancers, most frequently in melanoma. The BRAF p.G596R mutation found in GBM_10 is classified as a class III
BRAF mutation and is known to activate ERK signaling in a RAS-dependent manner despite impaired kinase
activity30. The fifth BRAF mutation, found in patient GBM_09, was a frameshift present at the beginning of the
kinase domain, and would thus be predicted to result in loss of function.
Comparison of tumors with EGFR and BRAF mutations. As expected, BRAF and EGFR mutations

were mutually exclusive in our cohort. EGFR gene amplifications and point mutations were only seen in primary
GBMs, while one of the BRAF mutations was found alongside a gain-of-function mutation in IDH1. The three
male and two female patients with SNVs in the BRAF gene were, on average, younger than the 21 patients with
EGFR SNVs (mean, 41.82 ± 15.94 and 53.19 ± 11.33 years, respectively).
The location of the tumor within the brain was known for 87 of the 91 specimens analyzed. Tumors were
found adjacent to the ventricular system in 3 of the 5 patients with BRAF mutations (Fig. 2A, Supplemental
Table 1). Of the two remaining BRAF-mutant tumors, one was found in the frontal lobe involving the precentral
gyrus and the location of the other was unknown. In comparison, tumors without BRAF mutations showed a
range of locations, most commonly involving the frontal and temporal lobes and, less frequently, the parietal
lobes, occipital lobes or midline structures (Supplemental Table 1).
The BRAF-mutant tumors in this cohort set did not exhibit distinctive histomorphology (Fig. 2B). None were
characterized as epithelioid GBM.

Impact of BRAF and EGFR mutations on survival. Survival data was available for 85 of 91 patients.
Kaplan–Meier curves were calculated to compare the outcomes of tumors with EGFR versus BRAF mutations

Scientific Reports |
Vol:.(1234567890)

(2021) 11:19999 |

https://doi.org/10.1038/s41598-021-99278-w

4

www.nature.com/scientificreports/

Figure 2.  Magnetic resonance imaging and histological features of a representative BRAF mutated tumor.
Patients with BRAF mutant GBMs were typically found adjacent to the ventricular system (A). BRAF mutated
tumors did not show distinctive histomorphology compared to classical GBM (B).

Figure 3.  The impact of BRAF versus EGFR mutations on overall survival in glioblastoma. Kaplan–Meier plots
indicate the difference in survival between BRAF and EGFR mutated tumors in our in-house cohort (A) and a
dataset from TCGA (B). Considering only IDH1 wild-type tumors, the average overall survival of three patients
with putative activating BRAF mutations was longer than that of 20 patients with EGFR mutations from the
in-house cohort (average overall survival of 48.01 ± 24.42 months versus 16.13 ± 11.46 months, respectively;
log-rank p = 0.02). One patient with an activating IDH1 mutation and another with a BRAF frameshift mutation
(likely loss-of-function) were omitted from this analysis. Likewise, the average overall survival of 6 patients with
gain-of-function BRAF mutations was longer compared to 77 patients with gain-of-function EGFR mutations in
a cohort from TCGA (average overall survival of 27.68 ± 26.95 and 14.19 ± 11.28 months, respectively; log-rank
p = 0.09).
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(Fig. 3A). Excluding GBM_01 (a secondary GMB) and GBM_09 (harboring the likely-inactivating frameshift
mutation), the average overall survival of three patients with BRAF-mutated tumors was longer than that of
patients with EGFR-mutated tumors (average of 48.01 ± 24.42 months versus 16.13 ± 11.46 months, respectively;
log-rank p-value = 0.02). These findings should be considered as preliminary given the small size of the BRAFmutated cohort.
We leveraged a TCGA dataset (Firehose Legacy, https://www.cbioportal.org/study?id=gbm_tcga) to further
explore the implications of BRAF mutations on survival outcomes. Mutation data was provided for 290 of the
619 specimens included in this cohort. Six of the 290 profiled tumors harbored gain-of-function mutations in
BRAF (5 p.V600E, 1 p.G596D) while 77 had gain-of-function mutations in EGFR. Consistent with our in-house
dataset, primary GBM patients with BRAF-mutated tumors survived somewhat longer than patients with EGFRmutated tumors (Fig. 3B; mean, 27.68 ± 26.95 and 14.19 ± 11.28 months, respectively; log-rank p-value = 0.09).

Differential gene expression in IDHwt‑GBM with BRAF and EGFR mutations. Microarray data
from the TCGA cohort described above was used to assess gene expression profiles in GBM with distinct mutation signatures (Table 1). mRNA expression data was only available for three IDHwt tumors with BRAF p.V600E
mutations. These were compared to expression data from 12 randomly selected IDHwt tumors with gain-offunction EGFR mutations (individuals described in Supplemental Table 5). We included a third group of tumors
with IDH1 mutations to help determine the relative directional change of the observed expression differences.
Counts of genes considered differentially expressed across the three comparisons are listed in Table 1.
Biological theme enrichment analysis indicated that tumors with BRAF gain-of-function mutations show
increased expression of genes implicated in MET pathway signaling, protein processing, immune function, and
invasion, among other features that might be expected in a tissue exhibiting intense metabolic activity and cell
growth/division (Fig. 4, Supplemental Fig. 3, Supplemental Video 1). Of note, we observed elevated expression of
several genes typically thought to be selectively expressed in trophoblasts, including a complement of pregnancyspecific glycoproteins (PSGs) and HLA-G (Supplemental Fig. 4).
Compared to the other two groups, tumors with IDH1 mutations showed a strong stem-like gene expression
profile (Fig. 4). This included increased expression of genes related to cell cycle / mitosis, transformation to a
mesenchymal phenotype, and Wnt signaling, as well genes involved in neurogenesis.
Little overlap was seen in the comparison of tumors with EGFR gain-of-function mutations to tumors with
BRAF versus IDH1 mutations (Fig. 4).
Compared to tumors with BRAF mutations, EGFR-mutant tumors showed elevated expression of genes
involved in cell cycle function, regulation of apoptosis, and diverse signaling cascades. They also showed
increased expression of gene in the ERBB2 signaling cascade relative to tumors with IDH1 mutations.

Discussion

In this study, we combined data from an in-house cohort of 89 patients with data from TCGA to explore the clinical significance of gain-of-function mutations in BRAF versus EGFR. As previously shown, activating mutations
in these genes were mutually exclusive, suggesting that the two subtypes may arise through a distinct mechanism that leads to different pathological and clinical features. Although BRAF-mutant GBM are rare, patients
with BRAF-mutant tumors were, on average, younger and survived longer relative to those with EGFR-mutant
tumors. Despite similar histomorphology, BRAF-mutant tumors often arose centrally in the brain, adjacent to
the ventricular system. Microarray studies indicated that BRAF-mutant tumors have a unique mRNA expression
profile compared to EGFR- and IDH1-mutant tumors, with upregulation of genes related to immune tolerance
and invasion, suggesting a unique mechanism for tumorigenesis in this subset of GBM.
The aim of this study was not to describe the genomic landscape of GBM tumors; this has been reported
elsewhere4,10. Relatively few genes were sequenced and analyzed in our in-house cohort, as the NGS panel was
selected for clinical and diagnostic purposes rather than research, and most clinical NGS panels are limited in
scope to minimize cost and analytical time. Furthermore, the presently described assay was not suitable for the
detection of gene fusions, some of which are known to activate BRAF and the MAPK p
 athway31. The size and
scope of the clinical NGS panel remains a limitation of this work though our results indicate that the in-house
cohort was similar to those described in the literature, particularly with respect to the frequency of EGFR and
BRAF mutations4,32,33. Further work will be needed to fully characterize the genomic profile of these two groups.
Patients with GBM harboring BRAF mutations presented earlier in life compared to those patients whose
tumors had EGFR mutations. In other studies, BRAF p.V600E mutations have been associated with epithelioid
features in GBM34. BRAF p.V600E mutations are common (~ 50% frequency) in epithelioid GBM, a sub-type
that often occurs in young adults and c hildren35. In contrast, only one of our BRAF mutated tumors was found
in a pediatric patient (GBM_08, Supplemental Table 1) and none were characterized as the epithelioid subtype.
The histological appearance was conventional in all BRAF-mutated specimens from our in-house cohort (Fig. 2).
While the histological appearance of the BRAF-mutant tumors included in this study was unremarkable, we
did note that three of the four patients with available clinical data had BRAF-mutant tumors located adjacent to
the ventricular system. Other studies have indicated that overall survival is decreased for GBM bordering the
lateral ventricles36. Despite the small cohort size, our analysis suggested that patients with BRAF-mutant tumors
may survive longer compared to tumors with EGFR mutations, which were most often found in the cerebral
lobes (Supplemental Table 1). This difference in overall survival should be considered as a preliminary finding,
as statistical significance was not achieved (likely due to the paucity of BRAF-mutant tumors). Furthermore,
the rarity of BRAF-mutated tumors precluded multi-variate analyses that could help elucidate the role of other
impactful features such as age or sex. Indeed, patient age may be a key factor in survival since patients with BRAF
mutant tumors were, on average, younger than patients with EGFR mutated tumors. Nonetheless, the potential
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Figure 4.  Biological concepts and themes enriched among genes differentially expressed between tumors
gain-of-function mutation in BRAF, EGFR, or IDH1. A pseudo-heatmap was constructed from the comparison
of biological themes associated with the differentially expressed genes identified from a microarray based
study of gene expression profiles among glioblastoma with gain-of-function mutations in BRAF, EGFR and
IDH1. Related biological themes that were associated with each list of differentially expressed genes (illustrated
in Supplemental Fig. 1) were grouped into higher-level clusters to facilitate comparison between the three
subgroups. Red indicates increased expression; blue indicates decreased expression.
difference in outcomes is interesting, particularly in the absence of targeted treatments (e.g., FDA-approved
BRAF inhibitors like dabrafenib and vemurafenib)37–39.
The most striking differences between BRAF mutant tumors compared to other groups of GBM were seen at
the level of gene expression. BRAF-mutant tumors showed a unique mRNA expression profile, with increased
expression of genes involved in immune modulation, including the HLA-G gene. HLA-G is a non-classical
human leukocyte antigen class I molecule that functions in fetal-maternal immune tolerance40. It is possible
that this profile serves a similar function in tumors, suppressing the anti-tumor response through interaction
with inhibitory receptors on immune c ells41. These findings could have implications for traditional checkpoint
inhibition therapy (anti-CTLA-4 or anti-PD-1), in that the expression of HLA-G could serve as an alternate route
for immune evasion in BRAF mutated GBM.
A host of PSGs were also upregulated in BRAF-mutated tumors, which resulted in a trophoblast-like gene
expression profile. PSGs are a collection of secreted glycoproteins abundant in maternal blood during pregnancy.
Like HLA-G, they play an important role in embryonic d
 evelopment42, and have been associated with upregulated
43–46
expression in various c ancers
. For example, studies have shown that PSG9 serves as a driver of angiogenesis in
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colorectal and hepatocellular c ancers47,48. There are marked similarities between tumor invasion and trophoblast
i mplantation49,50, so our results may suggest that BRAF-mutant GBM may co-opt trophoblast-like properties to
facilitate their growth and spread.
While we have presented evidence that EGFR- and BRAF-mutated classical GBM are biologically distinct, we
cannot state with certainty whether these differences are directly caused by the mutations identified in these two
genes. It is possible that these mutations represent markers of particular tumor types, rather than the direct cause
of their distinction. This is particularly true of EGFR mutations, which are known to correlate with various other
impactful alterations (e.g., TERT promoter mutations, gain of chromosome 7, loss of chromosome 10, etc.)10. It
is also possible that BRAF-mutated tumors are representative of a larger sub-type of non-EGFR-mutated GBM
rather than a unique entity of their own. Regardless, the unique features of these two groups warrant further
exploration.

Conclusions

BRAF-mutant GBM are very rare, especially in adult populations; however, differences in tumor location, survival
rates, and global gene expression profiles set this set of tumors apart from other GBM. Striking differences were
seen in comparison to tumors with EGFR gain-of-function mutations, another member of the same signaling
cascade. Although this cohort was modest in size, BRAF-mutant GBM constituted a unique subgroup with
potential implications for tumor biology and treatment.

Data availability

The clinical data generated from this study are available in the associated supplemental materials.
Received: 4 May 2021; Accepted: 9 September 2021
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